PT  - JOURNAL ARTICLE
AU  - ZUSTOVICH, FABLE
AU  - CARTEI, GIUSEPPE
AU  - PASTORELLI, DAVIDE
AU  - NICOLETTO, ORNELLA
AU  - GOTTARDO, FEDRA
AU  - DE ZORZI, LUCA
AU  - BIANCO, MASSIMO DAL
TI  - A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m<sup>2</sup>/min with or without Immunotherapy in Advanced Renal Cancer
DP  - 2007 Nov 01
TA  - Anticancer Research
PG  - 4461--4464
VI  - 27
IP  - 6C
4099  - http://ar.iiarjournals.org/content/27/6C/4461.short
4100  - http://ar.iiarjournals.org/content/27/6C/4461.full
SO  - Anticancer Res2007 Nov 01; 27
AB  - Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m2/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved